secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0001641172-25-014318
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ernexa completes second closing of $6M private placement; total $7M raised; expects to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Second closing on June 9, 2025: issued 47.7M shares and 9.3M pre-funded warrants for ~$6.0M gross proceeds.
- Combined with April 2 closing, total 57.7M shares and 9.8M warrants issued for ~$7.0M.
- Proceeds to be used for working capital and repaying certain notes.
- Company believes it now satisfies Nasdaq Stockholders' Equity Standard ($2.5M minimum) as alternative to Market Value Standard.
- Pre-funded warrants exercisable at $0.005 per share with 4.99%/9.99% beneficial ownership limitation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000164117225014318/0001641172-25-014318-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000164117225014318/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-014318

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer